Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves’ Disease

Table 1

Baseline clinical characteristics of patients with Graves’ disease.

Characteristic	Total patients ()
Age, years	44.1 ± 14.0
Sex (female, %)	67 (68.4%)
Follow-up duration, months	33.1 ± 14.0
BMI, kg/m^2	23.4 ± 3.2
Isthmus, mm	5.4 ± 3.2
Thyroid volume, cm^3	32.3 ± 21.0
Pre-RAI T3, ng/mL	1.85 ± 0.97
Pre-RAI free T4, ng/mL	2.05 ± 1.22
Undetectable TSH (n, %)	76 (77.6%)
Pre-RAI TRAb, IU/L	13.45 ± 14.21
Pre-RAI TSI, %	318.5 ± 208.7
RAI dose, mCi	11.7 ± 1.8
2-hour uptake, %	44.3 ± 22.5
24-hour uptake, %	66.0 ± 21.5
2-hour/24-hour ratio	0.65 ± 0.24
Serum selenium, μg/L	118.2 ± 17.1
Serum 25(OH)D, ng/dL	19.0 ± 9.1

Data are presented as mean ± SD or number (%). BMI: body mass index; RAI: radioactive iodine; TRAb: TSH receptor antibody; TSI: thyroid-stimulating immunoglobulin; 25(OH)D: 25-hydroxycholecalciferol.